Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes

Atherosclerotic cardiovascular disease remains a major cause of death and disability, especially for high-risk familial hypercholesterolemia individuals. PCSK9i (proprotein convertase subtilisin kexin type 9 inhibitors) reduce low-density lipoprotein cholesterol levels and cardiovascular event rates...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Circ Cardiovasc Qual Outcomes
Glavni autori: Myers, Kelly D., Farboodi, Niloofar, Mwamburi, Mkaya, Howard, William, Staszak, David, Gidding, Samuel, Baum, Seth J., Wilemon, Katherine, Rader, Daniel J.
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2019
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7665275/
https://ncbi.nlm.nih.gov/pubmed/31331194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCOUTCOMES.118.005404
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items